News stories about New England Nuclear (NASDAQ:LNTH) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. New England Nuclear earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned headlines about the medical equipment provider an impact score of 44.9019121443271 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:

How to Become a New Pot Stock Millionaire

LNTH has been the topic of several recent analyst reports. Zacks Investment Research upgraded New England Nuclear from a “hold” rating to a “buy” rating and set a $26.00 price objective on the stock in a research note on Friday, January 12th. ValuEngine upgraded New England Nuclear from a “hold” rating to a “buy” rating in a research note on Saturday, February 3rd. Finally, BidaskClub cut New England Nuclear from a “buy” rating to a “hold” rating in a research note on Tuesday, December 19th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company. New England Nuclear currently has a consensus rating of “Hold” and a consensus target price of $24.75.

Shares of New England Nuclear stock traded up $0.50 during trading hours on Tuesday, hitting $16.95. 73,339 shares of the company’s stock traded hands, compared to its average volume of 377,697. New England Nuclear has a 12-month low of $11.30 and a 12-month high of $24.45. The firm has a market cap of $603.88, a PE ratio of 16.95, a P/E/G ratio of 1.27 and a beta of 1.52. The company has a debt-to-equity ratio of 11.40, a current ratio of 3.16 and a quick ratio of 2.60.

New England Nuclear (NASDAQ:LNTH) last announced its earnings results on Monday, February 26th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.20 by ($0.08). New England Nuclear had a net margin of 37.23% and a negative return on equity of 68.13%. The business had revenue of $81.24 million for the quarter, compared to analysts’ expectations of $78.57 million. During the same period in the prior year, the business earned $0.18 earnings per share. The company’s revenue for the quarter was up 9.3% compared to the same quarter last year. equities analysts anticipate that New England Nuclear will post 1.04 EPS for the current fiscal year.

In other news, SVP Timothy G. Healey sold 3,696 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $19.58, for a total transaction of $72,367.68. Following the completion of the sale, the senior vice president now directly owns 64,582 shares of the company’s stock, valued at approximately $1,264,515.56. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Michael P. Duffy sold 27,313 shares of the firm’s stock in a transaction on Tuesday, April 3rd. The shares were sold at an average price of $15.30, for a total value of $417,888.90. Following the sale, the insider now directly owns 191,472 shares of the company’s stock, valued at $2,929,521.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 42,501 shares of company stock valued at $681,024. Insiders own 1.20% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “New England Nuclear (LNTH) Getting Somewhat Positive Press Coverage, Analysis Finds” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this story can be viewed at

About New England Nuclear

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow.

Insider Buying and Selling by Quarter for New England Nuclear (NASDAQ:LNTH)

Receive News & Ratings for New England Nuclear Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for New England Nuclear and related companies with's FREE daily email newsletter.